AVLN (49) RAPP (43) SPTX (56) MNKD (63) ⌘ Pro Terminal →

Amphastar Pharmaceuticals Inc. (AMPH) — RQD Stock Rating Cockpit

$26.93 +2.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Amphastar Pharmaceuticals Inc. (AMPH) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (50% profit margin, 9% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $1.15B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMPH)Realized 20D OHLCV Swing Band: ±6.9%

RSI-14 MOMENTUMBULLISH MOMENTUM

66.830 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.47>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE80% OF RANGE

L: $17$26.93H: $30

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (50% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 30 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on AMPH

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (65)

9.0% ROIC with 49.5% gross margin and 10.58% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 2.47 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (78)

30/40 institutional & smart-money positioning score with 17/20 macro alignment.

Bull Case: Why Buyers Like AMPH

✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (AMPH Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AMPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +22.63%▲ ASCENDING CHANNEL

2026-10-30O $27.12H $27.80L $26.76C $26.93VOL 664.5K

RES: $29.94SUP: $25.10SMA50: $24.76SMA200: $22.25

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMPH Butterfly Map → + Track AMPH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

2.0%/yr Implied 5Y Growth

vs. -1.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AMPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AMPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMPH)

Health Care Rank #85 of 1016 ⚔️ AVLN vs AMPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMPH vs. AVLN, RAPP, SPTX, MNKD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Amphastar Pharmaceuticals Inc. (AMPH) ranks #85 by composite RQD confidence (71/100, grade B-) and #343 by equity capitalization ($1.15B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. AMPH currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AMPH ACTIVE Amphastar Pharmaceuticals Inc.	B-	71/100	11.7x	49.5%	9.0%	+2.28%	$1.15B	Benchmark Subject
AVLN Avalyn Pharma Inc.	D	49/100	—	—	—	-0.12%	$1.14B	/avln-vs-amph →
RAPP Rapport Therapeutics Inc.	D-	43/100	—	—	-22.9%	+7.60%	$1.16B	/rapp-vs-amph →
SPTX Seaport Therapeutics Inc.	D+	56/100	—	—	—	+3.53%	$1.13B	/sptx-vs-amph →
MNKD MannKind Corporation	C	63/100	—	92.3%	54.5%	+2.04%	$1.13B	/mnkd-vs-amph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001297184

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amphastar Pharmaceuticals Inc. (AMPH) reported GAAP revenue of $719.9M (-1.7% vs. FY2024 revenue of $732.0M , and +11.7% cumulative change since FY2023) , GAAP net income of $98.1M, operating cash flow of $156.1M, and free cash flow of $121.2M (-29.7% YoY). On the balance sheet, AMPH closed FY2025 with $1.63B in total assets against $619.7M in total debt (Altman Z-Score: 2.47, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$719.9M	$98.1M	$156.1M	$121.2M	$1.63B	$619.7M
FY2024 (FY)	2024-12-31	$732.0M	$159.5M	$213.4M	$172.3M	$1.58B	$613.5M
FY2023 (FY)	2023-12-31	$644.4M	$137.5M	$183.5M	$183.5M	—	—

3. AMPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $26.93 (+2.28% 1D, market cap $1.15B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 17/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, AMPH ranks #85 in composite RQD confidence.

How does AMPH compare to AVLN and RAPP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMPH carries a Roarable B- (71/100 RQD), trailing P/E of 11.7x, gross margin of 49.5%, and ROIC of 9.0%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.14B) and RAPP (Rapport Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -22.9%, cap $1.16B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMPH?

Per AMPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001297184), Amphastar Pharmaceuticals Inc. generated $719.9M in revenue (-1.7% YoY), $98.1M in net income, and $121.2M in free cash flow against $1.63B in total assets and $619.7M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMPH trading relative to its 50-day, 200-day, and 52-week technical levels?

AMPH last traded at $26.93 (+2.28% on volume of 371,432 shares), positioning the stock +8.76% above its 50-day simple moving average ($24.76) and +21.03% above its 200-day simple moving average ($22.25). Across its 52-week range of $16.65 to $29.52, AMPH sits at the 79.9% percentile with a 14-day RSI of 66.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.9% ($25.07 to $28.79).

AMPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell AMPH stock right now?

Amphastar Pharmaceuticals Inc. (AMPH) currently earns a Roarable Rating of B- (Buy — BUY) with 71/100 RQD Confidence. High-quality cash engine (50% profit margin, 9% return on capital) with steady institutional support.

What is AMPH's 12-month price target and RQD AI Jury consensus?

AMPH's 12-month base price target is $28.51 (range $22.08 to $33.64), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: AMPH RQD Cockpit AMPH 12M Forecast AMPH Earnings & Move AMPH Dividends & DRIP AMPH Insiders & 13F AMPH Whale Options AMPH Profit Sankey AMPH News & Why